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Cell-mediated immunity plays a key role in the regression of papillomavirus-induced warts and intra-epithelial lesions but the target antigens
that induce this response are not clear. Canine oral papillomavirus (COPV) infection of the oral cavity in dogs is a well-characterized model of
mucosal papillomavirus infection that permits analysis of the immune events during the infectious cycle. In this study we show that during the
COPV infectious cycle, systemic T cell responses to peptides of several early proteins particularly the E2 protein, as assayed by delayed type
hypersensitivity, lymphoproliferation and IFN-γ ELISPOT, can be detected. The maximal response occurs in a narrow time window that coincides
with maximal viral DNA replication and wart regression: thereafter, systemic T cell responses to early proteins decline quite rapidly. Vaccination
using particle-mediated immunotherapeutic delivery (PMID) of codon-modified COPV E2 and E1 genes induces strong antigen-specific cell-
mediated immune responses in the vaccinated animals. These data show that therapeutic immunization by PMID with codon-modified E2 is
completely effective, that to E1 is partially protective, that this correlates with the intensity of antigen-specific cell-mediated immune responses
and, further, they emphasize the importance of these responses and the route of immunization in the generation of protective immunity.
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Papillomaviruses are small DNA viruses with a circular
double-stranded DNA genome of about 8 kb. The viruses are
exquisitely species and tissue-specific and can induce benign
epithelial proliferations or warts in both cutaneous and
mucosal squamous epithelia. A correlation between high-
risk human papillomavirus (HPV) infection and cervical
cancer has been well documented. DNA sequences of the
genital high-risk HPVs are detected in over 95% of cervical
cancers worldwide (Walboomers et al., 1999) and infection
with one of these viruses is the cause of cervical cancer
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doi:10.1016/j.virol.2006.07.032and low-risk types is not trivial. Cancer of the cervix is the
second commonest cancer in women worldwide with around
500,000 new cases diagnosed annually; ano-genital warts are
the commonest sexually transmitted viral infection in
developed societies and contribute significantly to health
care costs. Therapies for the control of benign warts or the
cancer precursors, intra-epithelial HPV-associated lesions, are
not always effective, do not usually eliminate infection and
can lead to recurrence (Levi et al., 1996; O'Mahony, 2005).
Prophylactic virus-like particle (VLP) vaccines against the
common genital HPV types have shown remarkable efficacy
in clinical trials (Harper et al., 2004; Koutsky et al., 2002;
Villa et al., 2005) but the effects of these vaccines will not be
evident for several decades and their implementation in
developing countries will pose huge challenges (Padma,
2005). Furthermore, they will not affect existing persistent
infection/disease and new treatments for such infections are a
matter of high priority. Immunotherapies are an obvious
approach but this does require an understanding of the
underlying immunobiology of infection and disease.
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pressed individuals (Benton and Arends, 1996) indicating that
cell-mediated immunity is important in their control. Regres-
sion of papillomavirus-induced warts is associated with T cell
infiltration both in humans (Coleman et al., 1994) and
animals (Okabayashi et al., 1991; Knowles et al., 1996;
Nicholls et al., 2001). The available evidence implicates
CD4+ T cells as having a key role in the initiation and regu-
lation of effective anti-papillomavirus immunity since these
are the most prominent lymphocyte subset infiltrating regres-
sing warts and intra-epithelial lesions. Furthermore, IFNγ
secreting CD4+ T cells specific for HPV 16 or 18 early pro-
teins can be detected readily in healthy female donors (de Jong
et al., 2002a,b; Welters et al., 2003), whereas T cells with the
same specificity are rarely found in individuals with cervical
cancer (de Jong et al., 2004; Welters et al., 2006) suggesting
that vaccines designed to induce strong Th1 type responses
could be effective particularly in early or low grade genital
HPV infections.
Natural infections in animals have provided very strong
evidence for the importance of cell-mediated immunity in
both natural infection and following vaccination. The
observation that passively transferred serum failed to clear
warts in the rabbit (Evans and Ito, 1966; Kidd, 1938), yet
offered protection from canine oral papillomavirus (COPV)
challenge in dogs (Suzich et al., 1995) implied that humoral
immunity was not involved in lesion regression suggesting
that cell-mediated responses must be crucial; a notion further
supported by the observation that, in the rabbit, seroconver-
sion was not required for regression of cotton tail rabbit
papillomavirus (CRPV)-induced papillomas (Selvakumar et
al., 1995a). Positive skin tests using viral proteins in rabbits
with regressing papillomas (Hopfl et al., 1993), together with
in vitro responses of peripheral blood lymphocytes to viral
proteins, clearly indicate active cellular immunity to CRPV.
Systemic cell responses to the viral E1, E2, E6 and E7
proteins have been seen in the rabbit, with those to E2 being
the strongest (Han et al., 1999; Selvakumar et al., 1995b).
Lymphoproliferative assays demonstrated E7-specific T cells
in cattle with naturally regressing papillomas (Chandrachud et
al., 1994; McGarvie et al., 1995), although the response was
much lower than that of cattle vaccinated with an E7 fusion
protein.
Although it is clear that cell-mediated immunity is central
to regression of papillomavirus-induced lesions and that
vaccination with early proteins has some therapeutic effect,
the identity of the viral proteins that initiate the responses and
the time at which these responses are maximal during the
infectious cycle remains uncertain. In the present study, we
have addressed these issues using COPV, a mucosal virus
infecting a well-characterized laboratory species and a model
with established utility in vaccine studies (Suzich et al.,
1995). We show that the E2 protein is the major cellular
immune target in the natural infectious cycle with maximal
systemic responses detectable just prior to wart regression.
We further show that effective therapeutic vaccination with
E2 DNA delivered by particle-mediated immunotherapeuticdelivery (PMID) elicits a strong E2-specific T cell response
and that route of immunization is important for maximal
efficacy.
Results
Natural infectious cycle
A group of 5 animals were challenged with COPV on their
upper lips by the scarification technique as described
previously (Stanley et al., 2001) and their wart development
monitored throughout the viral life cycle (Fig. 1). Warts
showed an expected pattern of growth and developed fully
grown mature papillomas at all the challenge sites (100% at
weeks 6–9). The first appearance of lesions was about week 5
after challenge (C+5), with a growth to a maximum diameter
by weeks 8–9 (C+8–9) followed by rapid regression until, at
week 12 post-challenge (C+12), the oral epithelium appeared
normal (Fig. 1). Regular blood sampling throughout this
period was used to study the systemic immune responses to
COPV early proteins E1, E2, E6 and E7. Cell viability was
checked using stimulation by the mitogen Con A and all cells
used were viable, proliferating strongly in response to Con A
(data not shown). The largest response detected was to the E2
peptides with smaller, but significant responses, to E1, E6 and
E7 peptides (Fig. 1). E2 responses showed an early peak
during the first stages of viral DNA replication when it is
likely that there would be significant E2 expression in the
infected site (weeks 3–4), with a declining response at
background levels for weeks 5 and 6. This correlates with the
plasmid maintenance phase of the infectious cycle when E1/
E2 expression is thought to be minimal (Peh et al., 2002).
This was then followed by a second and larger response at the
time of maximal viral DNA replication and the initiation of
wart regression (weeks 8–10). E6 and E7 responses were
maximal at week 7 when expression of these proteins is most
prominent (Nicholls et al., 1999).
Prophylactic early gene E1 vaccination
We have previously shown that PMID vaccination with
codon-optimized COPV E1 DNA in a prophylactic protocol
can completely protect animals from challenge with COPV
(Moore et al., 2002). It was observed in those experiments
that while HBVs vaccinated beagles developed fully grown
warts at all the sites, none of the animals vaccinated with
codon-optimized E1 developed warts at any site. The animals
immunized with wild-type E1 developed lesions that were
smaller than the HBVs group. These ‘micropapular lesions’
did not develop into fully grown florid papillomas and also
regressed much earlier than the control group. Regular blood
samples collected during this vaccination experiment were
analyzed in the current study to determine the antigen-specific
T cell response to this vaccine. A lymphoproliferation (LPA)
assay was developed and standardized to characterize canine
T cell responses to COPV peptides. A significant proliferation
to c/opt E1 was detected after only one vaccination (SI 9),
Fig. 1. T cell lymphoproliferative responses to COPV E1, E2, E6 and E7 peptide pools in beagles mimicking the natural history of virus infection. These beagles
received no vaccination, but were experimentally infected with COPV. The figure shows the average response in 5 animals. Responses are depicted as stimulation
indices. E2 elicits maximal responses. The graph also shows mean wart sizes of the 5 animals and it can be seen that wart regression correlates with maximal systemic T
cell responses. Y error bars denote standard error of the mean (SEM).
25S. Jain et al. / Virology 356 (2006) 23–34this response was boosted by the second vaccination (SI 15)
and then rapidly declined (Fig. 2). The results are shown as
an average across the group. All dogs vaccinated with the
codon-modified E1 gene showed similar T cell proliferative
patterns, although some were higher responders than others.
The responses were specific for COPV E1, as stimulation
with non-relevant antigens did not result in significant
proliferation (SI<2).
The LPA response in the codon-optimized group were
much more pronounced and occurred immediately after the
priming immunization when compared to animals that were
vaccinated with wt E1 (Fig. 1) or the non-relevant HBVs
gene (data not shown). This correlates with the non-
appearance of warts in codon-optimized E1 vaccinated
animals, and suggests that induction of an effective cell-Fig. 2. Comparison of antigen-specific T cell lymphoproliferative responses in dogs
stimulation indices (SI) and represent average responses seen in each group. A po
standard deviation (SD) The X-axis depicts the time course where, P=priming with
subsequent numbers refer to that number of weeks post prime (P), post boost (B) ormediated response early in the viral life cycle plays a
significant role in the complete protection conferred by this
vaccine. It also demonstrates the importance of antigen load
in the induction of an effective immune response as increased
expression of E1 protein by the codon-modified gene (Moore
et al., 2002) resulted in much more pronounced T cell
responses. In the wild-type E1 vaccinated group a consider-
ably lower proliferation was detectable at a later time point
(C+5) after what is presumably a second booster from E1
expressed during the natural life cycle. Overall systemic T
cell responses in this group were poor.
The control dogs vaccinated with the HBVs plasmid rarely
showed any significant proliferation to COPV E1 peptides.
The SI at all time points was less than 2, except at 9–
11 weeks post-challenge where it reached a maximum of 5.vaccinated with COPV wild-type and codon-optimized E1. Data are shown as
sitive lymphoproliferative response was defined by SI>2. Y error bars denote
antigen, B=boost with antigen and C=challenge with COPV. P+1 or B+1 and
post-challenge (C).
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and it appears that that the systemic T cell responses in this
group were minimal and occurred much later in the course of
disease than that seen in the vaccinated groups. Theobservation that control beagles did show proliferative
responses, although weak, indicated that systemic cell-
mediated immune responses to E1 are induced in the natural
life cycle of papillomaviruses.
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responses
We have shown previously that vaccination with a codon-
optimized COPV E2 gene after challenge with COPV can
impact significantly on disease (Moore et al., 2003) and Fig.
3A shows the mean wart size and percentage of sites that
developed lesions in these experiments. In the control (HBVs)
group, warts developed at nearly every challenge site (94%)
with a duration and diameter similar to that seen in earlier
experiments (Moore et al., 2002; Stanley et al., 2001). This
pattern of response was also observed in animals immunized
with vaccines encoding wt early genes with the majority of
the sites developing papillomas (>75%) of a similar size and
duration to the control group. The E1 wild-type vaccine may
have had a slight effect on disease burden but this was not
statistically significant (p<0.05). The codon-optimized vac-
cines, on the other hand, had a substantial impact on disease
burden by all measurements. Animals vaccinated with a
codon-optimized E1 developed warts at fewer than 50% of
challenge sites and were significantly smaller in size and far
shorter in duration, compared to the HBVs or wild-type
groups. Codon optimized E2 vaccinated animals were, on the
other hand, completely protected and developed no lesions
with the exception of a single small epithelial thickening that
persisted for less than 7 days in one of the animals. These
data suggest that therapeutic immunization by PMID with
codon-optimized papillomavirus early genes is effective and
emphasizes the importance of antigen load in the generation
of protective responses to papillomavirus proteins. To
determine cell-mediated immune (CMI) responses to E1 or
E2 during progression or prevention in the vaccinated animals
LPA and IFN-γ ELISPOT assays were employed.
Strong T cell responses as measured by LPA were observed
in both the E1 and E2 codon-optimized groups (Fig. 3B). The
peptide pools used to stimulate PBLs included peptides that
covered the entire ORFs (not just the immunodominant
epitopes), i.e., E1 for E1 vaccinated group, E2 for the E2
vaccinated group. Responses in the HBVs group were tested
separately for each of the peptide pools. Proliferative responses
were more pronounced for the E2 antigen in the E2 vaccinated
group and these responses were antigen-specific since lym-
phoproliferation assays with non-relevant peptides always gave
an SI<2. The immune responses showed a gradual increase
during the interval between prime and boost reaching maximal
levels 2 weeks after the boost, i.e., 6 weeks post-challenge with
virus. All the animals within each vaccinated group showed
similar patterns with systemic T cell immune responses
maximal after the boost gradually declining thereafter.Fig. 3. Cell-mediated response to E1 and E2 proteins in a therapeutic vaccine trial. V
(c/opt) and wild-type (w/t) genes; or with a non-relevant Hepatitis B virus surface anti
papillomas following COPV challenge. (B) T cell lymphoproliferative (LPA) respo
different time points (denoted as weeks after challenge C) were stimulated with pep
vaccinated beagles, both with the E1 peptide pool as well as the E2 peptide pool. The re
group. Y error bars at each time point represent standard deviation of mean. The res
always gave an SI<2. (C) IFN-γ ELISPOT responses for E1 and E2 vaccinated beag
challenge [C] and 6 weeks post-challenge [C+6] with infectious COPV. Negative coLPA responses in the HBVs control group were always lower
when compared to the groups vaccinated with codon-optimized
E1 or E2 genes. LPA could not be measured for all the dogs
receiving wild-type E1/E2 vaccination due to non-availability
of PBMC samples. However, proliferation responses in samples
that were available (1–2 dogs/group) were substantially lower
than the codon-optimized groups.
Cell-mediated responses were also characterized by enzyme
linked immunospot (ELISPOT) assays (Fig. 3C) optimized for
the detection and quantitation of IFN-γ secreting cells, at the
single cell level, in the canine model. PBMC were tested for
their ability to secrete IFN-γ in response to in vitro stimulation
with a pool of COPV E1 or E2 peptides. All animals vaccinated
with codon-optimized E1 or E2 mounted a strong IFN-γ
secreting T cell response with a peak at 6 weeks post-challenge.
It was interesting to note that the response was maximal in dogs
vaccinated with E2 and since complete protection was observed
in this group, it is reasonable to conclude that disease prevention
correlates with the induction of such antigen-specific, cellular
immune responses. The data suggest that E2 is more
immunogenic than E1 and imply that the complete protection
seen with the c/optE2 vaccine compared to the partial protection
achieved with c/optE1is due to the enhanced T cell response in
the E2 group. A time course for IFN-γ ELISPOT measured
responses could not be carried out due to limited amounts of
cells available. However, the increased response seen 6 weeks
post-challenge correlates with the observations made in
lymphoproliferative assays. The presence of IFN-γ secreting
cells in the vaccinated dogs suggests that vaccination-induced
protection/regression of disease is a Th1-mediated event and
may be an immune correlate for successful immunotherapeutic
intervention whether by vaccination or immunomodulation as
has been suggested in genital HPV infections (Baldwin et al.,
2003; van Poelgeest et al., 2005; Welters et al., 2006).
Identification of immunodominant epitopes in COPV E1 and
E2 proteins
Using a series of overlapping peptides (spanning the entire
sequence of COPV E1 and E2), specific immunodominant T
cell epitopes were identified. Each peptide was individually
tested in LPA for its ability to stimulate clonal proliferation of T
cells. Some peptides were more immunogenic in individual
dogs. These variations in immune selectivity are expected, as
the beagles were an outbred population and possess genetic
differences. However, some peptides were responders across
groups and these might be labeled as promiscuous epitopes as
they are capable of being bound by multiple MHC alleles. Very
high stimulation indices were observed with some peptidesarious groups represent dogs vaccinated with COPV E2 or E1 codon-optimized
gen (HBVs) (A) shows the mean wart size and percentage of sites that developed
nses in dogs vaccinated with codon-optimized E1 and E2. PBMC collected at
tide pools of E1 and E2 protein. LPA responses were also measured in HBVs
sponses are shown as stimulation indices and depict mean responses of the whole
ponses were antigen-specific as lymphoproliferation with non-relevant peptides
les. Results are shown as number of spot forming cells/105 cells as measured at
ntrol and unrelated peptide stimulated cells showed no spots.
28 S. Jain et al. / Virology 356 (2006) 23–34(Table 1) with some reaching 50. A cut-off of SI>10 was
considered to identify immunodominant epitopes.
Effect of route of vaccine administration on the induction of
CMI
Route of administration is known to influence vaccine
efficacy, particularly for DNA vaccines (van Rooij et al.,
1998; Loehr et al., 2000). In previous vaccine experiments,
undertaken by our group using the COPV model, vaccine was
delivered by a combined systemic (epidermis/dermis of belly)
and local mucosal (epithelium/stroma of the oral mucosa)
route. Since papillomavirus infections are exclusively intra-
epithelial and local, the route of vaccine delivery may be
important for therapeutic effectiveness. To investigate this,
different routes of vaccine administration were used to
identify the optimal route to elicit potent cellular immune
responses. Five (5) experimental groups each comprising 5
dogs, received vaccine either via the systemic route alone (6
sites skin of belly) and the skin of the head (to target the
draining nodes of the oral mucosa) or the local route alone (6
sites on the oral mucosa) or a combination of both (6 sites on
belly and oral mucosa). All were vaccinated with the E2
codon-optimized gene in a therapeutic protocol, i.e., viral
challenge at week 0, immunization at weeks 2 and 4 post-
challenge. A control group was immunized with an irrelevant
DNA vaccine (HBVs) via the combined systemic local (belly
and oral mucosa) route. The lymphatic drainage of the oral
mucosa in the dog is not well understood but in the delivery
to the head, immunization was to the skin at 6 sites overlying
the facialis and temporalis muscles with the objective of
targeting the lymph nodes thought to drain the oral mucosa,
i.e., the parotid, lateral retro-pharyngeal, mandibular and
medial retro-pharyngeal nodes. Vaccination via the oralTable 1
Immunodominant E1 peptides were identified in dogs vaccinated with E1 codon-op
Immunodominant E1 peptides
Sequence SI
71 LQQLKRKFVQSPQSRDLCSL 90 10.39 (2/3) a
121 SNEADDSLEGQRQVEPLPGR 140 15.42 (3/3)
131 QRQVEPLPGREENGADALFK 150 14.97 (3/3)
181 KTCSSDWVVCLYHVSDDRRE 200 13.47 (3/3)
261 SPAVALYWYKKGFASGTFTH 280 16.71 (3/3)
281 GELPSWIAQQTLITHHLAAE 300 16.44 (3/3)
291 TLITHHLAAEKTFDLSEMVQ 310 11.32 (3/3)
371 SQWIDERCKATDDGPGDWKE 391 10.46 (2/3)
381 TDDGPGDWKEVVKFLRHQGI 400 10.47 (3/3)
Total number of dogs in this group was 5, however only 3 were tested for all the
Immunodominant E2 peptides were identified in codon optimized E2 vaccinated do
Numbers flanking sequence denote the start and end amino acid position of the respec
a Responding beagles/number of total dogs.mucosal route was regarded as local immunization since
antigen presentation and processing would be via the
dendritic cells at the sites of immunization (and subsequent
viral challenge) with T cell activation in the nodes draining
those sites.
Following viral challenge, development of papillomas was
monitored, measured, and documented (Fig. 4A). Dogs
vaccinated via the oral mucosa alone or by combined
mucosal/belly delivery did not develop any warts. Dogs
receiving only a cutaneous delivery (belly or head) showed
small lesions at the majority of challenge sites (>70%) with 2
dogs in each group developing full-grown mature warts (40%
of sites). However, with the exception of these warts, the
other lesions which appeared were significantly smaller and
regressed very quickly, i.e., within 2–3 weeks. This suggests
that the local mucosal route (immunization at site of
challenge with virus and development of lesions) is a better
route for immunization but that the cutaneous route although
helping to reduce disease burden and conferring partial
protection, is not as effective. The cellular immune response
data support the biological readout (Figs. 4B–D). Fig. 4B
compares lymphoproliferative responses in the different
groups; the data are shown as an average of each group.
Antigen-specific T cell responses are seen only for the belly–
mucosal and mucosal routes and are much more pronounced
in the former.
Cellular immune responses to E2 in response to therapeutic
vaccination were also measured by the delayed type hypersen-
sitivity (DTH) test (Fig. 4D). Recombinant adenovirus encod-
ing COPV E2 was used as the recall antigen and was injected
intradermally in one ear. Control adenovirus (encoding green
fluorescent protein) was injected in the other ear and swelling
was measured 48 h after antigen challenge. Maximal swelling
was observed in the group that was immunized via the belly–timized vaccine
Immunodominant E2 peptides
Sequence SI
21 QNQSLADQSRHWSLLRKEQ 40 29.4 (6/6)
31 RHWSLLRKEQVLLYYARGKG 50 61.4 (6/6)
51 IMRIGMQPVPPQSVSQAKAK 70 16.8 (5/6)
71 QAIEQSLYIDSLLHSKYANE 90 44.8 (6/6)
111 KKGGKQIDVRYGDSEENIVR 130 24.0 (3/6)
131 YVLWLDIYYQDEFDTWEKAH 150 53.3 (6/6)
141 DEFDTWEKAHGKLDHKGLSY 160 33.4 (6/6)
171 DFEEEANKYSETGKYEILNQ 190 14.5 (4/6)
181 ETGKYEILNQPTTIPTTSAA 200 13.1 (3/6)
231 GRRSSRFPRRSGGRGRLGRG 250 29.3 (4/6)
241 SGGRGRLGRGGSGELPPQPQ 260 31.0 (5/6)
251 GSGELPPQPQPSSSWSPPSP 270 24.3 (4/6)
271 QQVGSKHQLRTTSSAGGRLG 290 36.2 (6/6)
311 LKCIRYRLSHKHRGLYLGAS 330 65.3 (6/6)
341 GASKHDRGSARMLLAFLSDQ 360 32.4 (5/6)
366 MDRVTFPKSVRVFRGGLDEL 385 37.4 (6/6)
peptides due to non-availability of PBMC samples for the remaining 2 dogs.
gs. SI seen is average of responders across the group.
tive peptides. COPV E1 protein has 597 amino acids and E2 protein has 385 aa.
Fig. 4. CMI response to different routes of vaccine administration. 5 experimental groups each comprising 5 dogs were vaccinated with pHBVs through the systemic
and local route (belly and oral mucosa) or with pCOPV c/optE2, either through the systemic cutaneous route (belly), systemic cutaneous route targeting oro-pharyngeal
draining lymph nodes (head), local mucosal (oral) or a combination of both systemic and local (belly skin and oral mucosa). (A) True mean wart size. All challenge
sites were included irrespective of whether lesions had developed at these sites or not thus the true mean includes sites with 0-mm lesions as opposed to a mean of the
average size only of warts that developed. (B) E2-specific LPA responses in beagles receiving immunization through different routes. PBMC were assayed for
proliferation using E2 peptide pools, 11 weeks post-challenge (samples were available for this time point alone) and the data are represented as the average within each
group. Y error bars denote standard deviation of mean. (C) IFN-γ ELISPOT responses were measured to detect antigen-specific T cells secreting IFN-γ after antigen
stimulation. Results are shown as number of spot forming cells/105 cells as measured at week 0 when the dogs were challenged with COPV (C); and weeks 5 and 10
post-challenge (C+5 and C+10 respectively). When stimulated with a non-relevant antigen, the numbers of spot forming cells/105 were always <2 implying that the
responses are antigen-specific. (D) DTH test results as measured in dogs vaccinated through different routes of immunization. Data are depicted as average response
within each group. The negative measurement in the belly–mucosal group was due to 2 dogs showing a reduction in measured thickness post-injection with the control
Ad-GFP.
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route. DTH responses in the head and belly vaccinated animals
were poor and these were the groups in which papillomas
developed whereas the belly–mucosal and mucosal groups
were completely protected. These observations imply that
strong skin test reactions correlate with effective CMI in the
vaccinated animals.
IFN-γ ELISPOTS were carried out for quantitative
evaluation of antigen-specific T cells. All the vaccinated
dogs had primed T cells directed against COPV E2 peptides,
5 and 10 weeks post-challenge with virus, as observed in
ELISPOT assays (Fig. 4C). The belly–mucosal group
appeared to have the maximal number of IFN-γ producing
T cells at 5 weeks post-challenge, however, all the vaccinated
groups show similar responses at week 11 post-challenge. The
responses are likely to be antigen-specific since the HBVs
vaccinated control group had an average of <2 spot forming
cells. Overall the data reinforce the notion that if a strong
cellular immune response to papillomavirus infection is to be
achieved then local immune activation (achieved in this study
by vaccination) combined with systemic immunization will be
the optimal strategy.Discussion
The temporal and spatial pattern of viral gene expression
during the COPV infectious cycle (Nicholls et al., 1999; Peh et
al., 2002) implies that early non-structural proteins will be the
targets of immune attack in post-exposure infection and
established disease. The data generated in this study show
that systemic T cell responses to early COPV proteins are
detectable during the infectious cycle but only in relatively
narrow time windows that correlate with phases of viral DNA
replication and amplification of viral copy number. The peak
systemic T cell response occurs at the time of papilloma
regression, weeks 8–10 of the infectious cycle. Although
detectable these systemic responses were only moderate in
amplitude when compared with the intensity of the mono-
nuclear infiltrate observed in the papillomas at the same time.
The dominant systemic T cell response was to E2 peptides
with smaller but significant responses to E1, E6 and E7. These
responses could be detected first at weeks 3–4 post-challenge.
Previous studies (Nicholls et al., 1999) showed that during the
infectious cycle, COPV DNA is first detected in the deep tips of
the rete ridges of the infected epithelium at week 4 post
30 S. Jain et al. / Virology 356 (2006) 23–34infection, and it seems feasible that the T cell response observed
at weeks 3–4 is to this first burst of viral replication and
episomal amplification. Systemic T cell responses fall to
background levels at weeks 5–6, coinciding with the phase of
plasmid maintenance in the infectious cycle, rising again and
peaking at weeks 8–10 when warts are regressing and then,
declining rapidly, as the oral epithelium returns to normal.
These systemic T cell responses parallel the events seen
histologically in the papillomas but the intensity of the systemic
T cell response is trivial compared to the magnitude of the
immune infiltrate into the lesion. E2 has been shown also to be a
key antigenic target in the rabbit where lymphoproliferative
responses against the E2 protein correlated with spontaneously
regressing CRPV-induced papillomas (Selvakumar et al.,
1995a).
The importance of E2 as an antigenic target in spontaneous
regression of COPV papillomas reinforces the notion that E2
vaccines will be therapeutically effective. Wild-type COPV E1
and E2 vaccines had little effect delivered either in a therapeutic
or prophylactic protocol, but vaccines consisting of E2 and E1
codon-modified sequences, had a dramatic impact on disease
development (Johnston et al., 2005; Moore et al., 2002, 2003).
The influence of codon usage on the immunogenicity of
polynucleotide vaccines for viral infection has been shown in
several studies (Andre et al., 1998; Vinner et al., 1999; zur
Megede et al., 2000). The effect of codon modification in the
COPV studies is probably due to increased antigen load as a
consequence of best codon usage: papillomavirus genes express
at relatively low levels in mammalian cells even when under the
control of strong heterologous promoters since codon usage is
not optimal (Zhou et al., 1999). Increased levels of protein
expression should lead to the induction of a more potent cell-
mediated immune response but, speculatively, the effect may
also be due to enhanced protein expression in dendritic cells
with a more appropriate tRNA synthetase expression.
E1 provided complete protection prophylactically and partial
protection when delivered post-exposure to virus but E2 not
only conferred complete protection from development of
papillomas both before and after COPV infection, but also
elicited the strongest T cell responses. E2 and E1 vaccines have
been tested prophylactically in both BPV (Campo, 1997) and
CRPV infections (Han et al., 1999; Selvakumar et al., 1995b)
but complete protection using only one early gene has been
shown only when codon-modified genes are used (Johnston et
al., 2005; Moore et al., 2002, 2003). E2-specific immunization
was shown to enhance regression of CRPV-induced papillomas
(Selvakumar et al., 1995b) but a codon-modified E2 expressed
via a recombinant adenovirus-induced regression of established
papillomas in the CRPV model (Brandsma et al., 2004).
There is no published data on immune responses to E1 in
humans but cell-mediated responses are made to E2 in genital
HPV infections. A non-intervention follow-up study of women
with cytological evidence of low grade CIN, showed that
HPV16 E2-specific T cell responses, as measured by specific
IL-2 release in vitro, occurred frequently at the time of lesion
clearance (Bontkes et al., 1999). Good Th1-type immunity
against the E2 and E6 protein has been detected in healthyindividuals with no clinical signs of HPV16 infection (de Jong
et al., 2002a,b; Welters et al., 2003). Importantly, these Th1 type
responses were found only occasionally in high-grade CIN
patients and were impaired in cervical cancer patients (de Jong
et al., 2004). These data suggest that a hall mark of effective
immune control of HPV 16 infection in the cervix is the
generation of CD4+ T cells specific for E2 and E6.
The data from both the natural infectious cycle and the
vaccination studies show that systemic T cell responses can be
detected only in narrow time windows. In the natural infectious
cycle measurable systemic Tcell responses appeared to coincide
with phases of viral DNA amplification. In the vaccination
experiments systemic responses could be detected at a very
early stage (3 weeks after primary vaccination) in the E2 codon-
optimized vaccinated group, suggesting that early induction of
potent immune responses does not allow the virus to establish a
productive infection. Furthermore, maximal T cell proliferative
responses in groups developing warts, preceded the biological
resolution of wart disease. Systemic responses declined quite
rapidly after reaching a peak and disappeared suggesting that
once the disease is resolved antigen-specific T cells can no
longer be detected in the periphery with the assay methods used.
It is possible that in the absence of high levels of persistent
antigen, the activated circulating T cells/memory T cells go back
to the site of infection and recirculate from the draining lymph
node through the epithelium. Some of these might remain in
systemic circulation, but at very low levels. The length of the
COPV infectious cycle is short (Nicholls et al., 1999) compared
to genital HPVs (Carter et al., 2000) and the data suggest that it
will be easy to miss a genuine systemic CMI to genital HPV
infection unless samples are taken in the appropriate time
windows during infection.
Peptide mapping studies revealed that COPV E1 and E2
contain a few immunodominant epitopes along with some
minor epitopes, which were recognized by more than one
animal in the respective groups. There were differences in
response to individual peptides in these animals, though this is
not surprising in an out-bred population possessing differing
MHC alleles. The presence of common reactive epitopes
suggests that perhaps these are promiscuous peptides and
therefore different MHC alleles might be capable of binding
these peptides and presenting them to peptide-specific T cells.
Papillomavirus infections result initially, in local, intra-
epithelial disease and strong appropriate and targeted local
immune responses would be predicted to be mandatory for
effective disease control and resolution. The route of immuni-
zation and the activation of local DC and local immunity may be
crucial in inducing such responses and the data in the present
study support this notion. Several routes of immunization –
systemic alone, local alone or combined systemic local – were
used to deliver codon-optimized E2 in a therapeutic regime.
Only protocols in which local immunization was used were
protective with a combined local/systemic combination result-
ing in complete protection. Cellular immune assays including
DTH skin tests, lymphoproliferation and IFN-gamma ELISPOT
showed that the strongest responses were elicited by the
combined local/systemic route and supported the results of the
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priming followed by a systemic boost might be the optimal
therapeutic vaccination protocol for papillomavirus-induced
disease. Local priming of the genital mucosa in women by
vaccination would be challenging but the importance of
eliciting a strong localized immune response is evident. In
this context new adjuvants that specifically target and activate
innate immune sensors with the activation and maturation of
epithelial dendritic cells may be crucial for therapeutic
papillomavirus vaccines.
Methods
Animals
Female or male beagles of age 8–12 weeks were obtained
from Harlan, UK, and housed in a purpose built, dog facility.
Fiberglass dividers were placed between pens of different
groups to minimize cross-infection and all animal handling
personnel followed barrier infection control protocols. At the
end of the experiment, all animals were humanely killed by
intravenous injection of sodium pentobarbitone. All animal
procedures were carried out in accordance with the regulations
set in “The Animals (Scientific Procedures) Act 1986”.
Vaccination protocol
Vaccinations were performed using a prime and boost
strategy and employing the Powderject XR device as described
previously (Stanley et al., 2001). The plasmids used were those
described previously pCOPV E1 wild-type (w/t) and codon
optimized (c/opt), pCOPV E2 w/t and c/opt, pHBVs (Moore et
al., 2002, 2003). DNA vaccines were delivered into the upper
oral (lip) mucosa, three sites on each side, and mid-ventral
abdominal skin (three sites on each adjacent side of the linea
alba). Each dog received a total dose of 8 μg DNA on each of
the two immunizations. Challenge with COPV 2 weeks after
boosting was performed on the buccal mucosa close to the sites
of oral immunization.
Viral challenge
Animals were subjected to general anaesthesia and the
mucosa of the upper lips was lightly scarified using the end tip
of a scalpel blade. Five sites per side of the upper lip were
scarified over an area of approximately 10×10 mm per site. An
aliquot of 10 μl of purified COPV suspension (approximately
45 ng of COPV L1 protein), isolated and characterized from a
clinical case of oral papillomatosis (Nicholls et al., 1999), was
applied over each scarified site using a pipette. The suspension
was allowed to be absorbed for about 3–5 min.
Prophylactic vaccination schedule
The vaccination comprised 5 animals that received codon-
optimized COPV E1 (pCOPV E1c/opt), 5 that received COPV
E1 wild-type (pCOPV E1wt) and 4 control animals receiving anon-relevant Hepatitis B virus surface antigen (pHBVs).
Booster vaccinations were delivered on the sixth week
following primary immunization and performed in the same
manner. Each dog received a total dose of 8 μg DNA on each of
the two immunizations. Four weeks after boosting, all dogs
were challenged with COPV.
Therapeutic vaccination schedule
The study included 6 experimental vaccine groups, each
comprising four beagles. Following challenge with COPV,
DNA plasmids encoding COPV L1 (pCOPV L1) and codon-
optimized and wild-type E1 (pCOPV E1c/opt, pCOPV E1wt) or
E2 (pCOPV E2c/opt, pCOPV E2wt) were delivered into oral
mucosal and cutaneous sites in beagles using PMID. Two weeks
post-challenge a priming dose of 8 μg DNA was delivered
followed by a booster dose after a further 2 weeks. A group of
control dogs were vaccinated using the non-relevant HBVs
antigen. Blood samples were taken prior to challenge and every
2 weeks thereafter.
Statistical methods
The mean diameter of papillomas for each dog was analyzed
using a mixed model analysis of variance. The model contained
a random effect for dogs (variation between dogs) and residual
error (variability within dogs). Pairwise comparisons of the
control HBVs group to the vaccinated groups were made at
each week using Fisher's LSD test with a confidence interval of
95%.
Recombinant adenovirus production
Recombinant adenoviruses expressing the E2 and E1 genes
of COPV were made using the “admid” system (Richards et al.,
2000), a generous gift from Glaxo Smith Kline Medicines
Research, Stevenage, Herts, UK. Before use, the recombinant
viruses were purified on cesium chloride gradients and virus
titer determined by plaque assay.
Peptide composition
Peptides spanning the entire open reading frames (ORFs)
of COPV E1, E2, E6 and E7 genes were synthesized and
purified by Chiron Mimotopes, Australia. Each peptide set
was composed of 20-amino-acid residues overlapping by 10
giving a total of one hundred and ten (110) 20mers.
Lyophilized peptides were resuspended in either DMSO
(>50% hydrophobicity) or 40% (v/v) acetonitrile–HEPES
solution before sonicating at 22-μm amplitude. Sonication
was performed on ice for a total of 5 min, in 60-s bursts, with
30-s intervals in between bursts. More DMSO was added to
peptides that remained insoluble after sonication. Dilute acetic
acid (0.15–10%) was also used to dissolve some positively
charged or basic peptides. Acetonitrile–HEPES solution or
distilled water was added to give a final concentration of
4 μg/μl. Peptides were used as pools spanning the entire ORF
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equaling 2.5, 5 or 10 μg/ml.
Isolation of canine PBMC (Peripheral Blood Mononuclear
Cells)
Blood samples were collected by venipuncture, once
preceding immunization and weekly thereafter. Ten (10) ml of
blood was collected from the jugular vein in a 15-ml sterile
plastic tube (Falcon) containing 100 μl of 100 mg/ml EDTA.
PBMC were isolated by density gradient centrifugation using
Ficoll-Paque (Pharmacia). The cells were collected at the
interface of the layers, diluted with an equal volume of chilled
media (RPMI-1640 with 2 mM L-glutamine, heat-inactivated
fetal calf serum (FCS), 100 IUpenicillin/100 μg/ml streptomy-
cin, 10 mmHEPES, 50 μM β-mercaptoethanol) and centrifuged
at 2000 rpm for 5 min. After resuspension cells were counted
and checked for viability by trypan blue exclusion and either
frozen (50% FCS, 40% RPMI, 10% DMSO) until use, or used
fresh for proliferation assays.
Lymphocyte proliferation assay
In a 96-well round bottomed microplate (Falcon), antigens
were added in 100 μl of RPMI with 10% FCS per well and
arranged in triplicates. The antigens used were pools of peptides
for the early genes E1, E2 or E7 at a concentration of 10 μg/ml,
5 μg/ml or 2.5 μg/ml. Wells containing medium only including
peptide resuspension solution served as negative controls.
1×105 PBMC in 100 μl of RPMI with 10%FCS were added to
each well. The cells were then incubated for 6 days at 37 °C
with 5% CO2. Concanavalin(Con A) at a concentration of
2.5 μg/ml was used as a positive proliferating agent and was
added 48 h prior to 3H-thymidine incorporation. 3H-thymidine
(Amersham) at 1 μCi/well was added on the sixth day and the
cells incubated for a further 16–18 h. Cells were then harvested
using a Wallac cell harvester onto filter mats and read using a
Wallac beta plate scintillation counter. T cell proliferative
responses were represented by Stimulation Indices (SI),
calculated by dividing the mean counts per minute (cpm) of
the triplicate samples with the mean cpm of the negative control
samples.
Canine IFN-γ ELISPOT assay
The ELISPOT assay was carried out for quantitative
determination of the frequency of cells releasing interferon
gamma (IFN-γ˜) Briefly, a monoclonal antibody for canine IFN-
γ (R&D Systems) was precoated onto a PVDF (polyvinylidene
difluoride)-backed microplate (Millipore). Cells stimulated with
E2, E1 peptide pools, Con A (positive control) or medium alone
(negative control) were pipetted into the wells and the
microplate placed into a humidified 37 °C carbon dioxide
(CO2) incubator for 48 h. The wells were then aspirated and the
plate washed four times with wash buffer (phosphate-buffered
saline/0.1% Tween): 100 μl of biotinylated polyclonal detection
antibody (R&D Systems) was added into each well andincubated at 4 °C overnight. After washing to remove any
unbound antibody, alkaline-phosphatase conjugated to strepta-
vidin was added and the plates incubated for 2 h at room
temperature. Unbound enzyme was subsequently removed by
washing and a substrate solution (BCIP/NBT) was added and
left for 1 h at room temperature, protected from light. The
chromogen solution was discarded and the plate dried. Positive
pink spots were counted by visualization using a dissecting
microscope.
Delayed type hypersensitivity response
A delayed type hypersensitivity (DTH) response to COPV
E2 protein in vaccinated beagles using a recombinant replica-
tion deficient adenovirus expressing E2 was measured. Six days
post-exposure, an intra-dermal injection of 1×106 pfu E2
adenovirus in 0.5 ml of phosphate-buffered saline (PBS) was
given to the right ear of each animal and an injection of
1×106 pfu of a control recombinant adenovirus expressing
green fluorescent protein (GFP) given to the left ear. The
thickness of each ear was measured using digital callipers at
48 h after injection.
Acknowledgments
The authors would like to thank Dawn Ward and Emily
Ikelle for their excellent technical assistance throughout this
project. This work was supported by a Research grant from
Glaxo Smith Kline Research and Development UK and the
Isaac Newton Trust Trinity College, University of Cambridge
UK.
References
Andre, S., Seed, B., Eberle, J., Schraut, W., Bultmann, A., Haas, J., 1998.
Increased immune response elicited by DNA vaccination with a synthetic
gp120 sequence with optimized codon usage. J. Virol. 72, 1497–1503.
Baldwin, P.J., van der Burg, S.H., Boswell, C.M., Offringa, R., Hickling, J.K.,
Dobson, J., Roberts, J.S., Latimer, J.A., Moseley, R.P., Coleman, N.,
Stanley, M.A., Sterling, J.C., 2003. Vaccinia-expressed human papilloma-
virus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal
intraepithelial neoplasia. Clin. Cancer Res. 9, 5205–5213.
Benton, E.C., Arends, M.J., 1996. Human papillomavirus in the immunosup-
pressed. In: Lacey, C. (Ed.), Papillomavirus Reviews: Current Research on
Papillomaviruses. Leeds University Press, Leeds, pp. 271–279.
Bontkes, H.J., de Gruijl, T.D., Bijl, A., Verheijen, R.H., Meijer, C.J., Scheper,
R.J., Stern, P.L., Burns, J.E., Maitland, N.J., Walboomers, J.M., 1999.
Human papillomavirus type 16 E2-specific T-helper lymphocyte responses
in patients with cervical intraepithelial neoplasia. J. Gen. Virol. 80,
2453–2459.
Brandsma, J.L., Shlyankevich, M., Zhang, L., Slade, M.D., Goodwin, E.C.,
Peh, W., Deisseroth, A.B., 2004. Vaccination of rabbits with an adenovirus
vector expressing the papillomavirus E2 protein leads to clearance of
papillomas and infection. J. Virol. 78, 116–123.
Campo, M.S., 1997. Vaccination against papillomavirus in cattle. Clin.
Dermatol. 15, 275–283.
Carter, J.J., Koutsky, L.A., Hughes, J.P., Lee, S.K., Kuypers, J., Kiviat, N.,
Galloway, D.A., 2000. Comparison of human papillomavirus types 16, 18,
and 6 capsid antibody responses following incident infection. J. Infect. Dis.
181, 1911–1919.
Chandrachud, L.M., O'Neil, B.W., Jarrett, W.F., Grindlay, G.J., McGarvie,
G.M., Campo, M.S., 1994. Humoral immune response to the E7 protein
33S. Jain et al. / Virology 356 (2006) 23–34of bovine papillomavirus type 4 and identification of B-cell epitopes.
Virology 200, 98–104.
Cogliano, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F.,
2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6,
204.
Coleman, N., Birley, H.D., Renton, A.M., Hanna, N.F., Ryait, B.K., Byrne, M.,
Taylor Robinson, D., Stanley, M.A., 1994. Immunological events in
regressing genital warts. Am. J. Clin. Pathol. 102, 768–774.
de Jong, A., van der Burg, S.H., Kwappenberg, K.M., van der Hulst, J.M.,
Franken, K.L., Geluk, A., van Meijgaarden, K.E., Drijfhout, J.W., Kenter,
G., Vermeij, P., Melief, C.J., Offringa, R., 2002a. Frequent detection of
human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
Cancer Res. 62, 472–479.
de Jong, A., van der Burg, S.H., Kwappenberg, K.M.C., van der Hulst, J.M.,
Franken, K.L.M.C., Geluk, A., van Meijgaarden, K.E., Drijfhout, J.W.,
Kenter, G., Vermeij, P., Melief, C.J.M., Offringa, R., 2002b. Frequent
detection of human papillomavirus 16 E2-specific T-helper immunity in
healthy subjects. Cancer Res. 62, 472–479.
de Jong, A., van Poelgeest, M.I., van der Hulst, J.M., Drijfhout, J.W., Fleuren,
G.J., Melief, C.J., Kenter, G., Offringa, R., van der Burg, S.H., 2004. Human
papillomavirus type 16-positive cervical cancer is associated with impaired
CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64,
5449–5455.
Evans, C.A., Ito, Y., 1966. Antitumor immunity in the Shope papilloma-
carcinoma complex of rabbits: 3. Response to reinfection with viral nucleic
acid. J. Natl. Cancer Inst. 36, 1161–1166.
Han, R., Cladel, N.M., Reed, C.A., Peng, X., Christensen, N.D., 1999.
Protection of rabbits from viral challenge by gene gun-based intracutaneous
vaccination with a combination of cottontail rabbit papillomavirus E1, E2,
E6, and E7 genes. J. Virol. 73, 7039–7043.
Harper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G., Jenkins, D., Schuind, A.,
Zahaf, T., Innis, B., Naud, P., De Carvalho, N.S., Roteli-Martins, C.M.,
Teixeira, J., Blatter, M.M., Korn, A.P., Quint, W., Dubin, G., 2004. Efficacy
of a bivalent L1 virus-like particle vaccine in prevention of infection with
human papillomavirus types 16 and 18 in young women: a randomised
controlled trial. Lancet 364, 1757–1765.
Hopfl, R.M., Christensen, N.D., Angell, M.G., Kreider, J.W., 1993. Skin test to
assess immunity against cottontail rabbit papillomavirus antigens in rabbits
with progressing papillomas or after papilloma regression. J. Invest.
Dermatol. 101, 227–231.
Johnston, K.B., Monteiro, J.M., Schultz, L.D., Chen, L., Wang, F., Ausensi,
V.A., Dell, E.C., Santos, E.B., Moore, R.A., Palker, T.J., Stanley, M.A.,
Jansen, K.U., 2005. Protection of beagle dogs from mucosal challenge with
canine oral papillomavirus by immunization with recombinant adenoviruses
expressing codon-optimized early genes. Virology 336, 208–218.
Kidd, J.G., 1938. The course of virus-induced rabbit papillomas as determined
by virus cells, and host. J. Exp. Med. 67, 551–574.
Knowles, G., O'Neil, B.W., Campo, M.S., 1996. Phenotypical characterization
of lymphocytes infiltrating regressing papillomas. J. Virol. 70, 8451–8458.
Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E., Alvarez, F.B.,
Chiacchierini, L.M., Jansen, K.U., 2002. A controlled trial of a human
papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651.
Levi, F., Randimbison, L., La Vecchia, C., Franceschi, S., 1996. Incidence of
invasive cancers following carcinoma in situ of the cervix. Br. J. Cancer 74,
1321–1323.
Loehr, B.I., Willson, P., Babiuk, L.A., van Drunen Little-van den Hurk,
2000. Gene gun-mediated DNA immunization primes development of
mucosal immunity against bovine herpesvirus 1 in cattle. J. Virol. 74,
6077–6086.
McGarvie, G.M., Grindlay, G.J., Chandrachud, L.M., O'Neill, B.W., Jarrett,
W.F.H., Campo, M.S., 1995. T-cell responses to BPV-E7 during infection
and mapping of T-cell epitopes. Virology 206, 504–510.
Moore, R.A., Santos, E.B., Nicholls, P.K., White, K.L., Anderson, D.M.,
Lloyd, A., Topley, P., Romanos, M., Thomsen, L., Parmar, V., Walcott, S.,
Gough, G.W., Stanley, M.A., 2002. Intraepithelial DNA immunisation with a
plasmid encoding a codon optimised COPV E1 gene sequence, but not the
wild-type gene sequence completely protects against mucosal challenge with
infectious COPV in beagles. Virology 304, 451–459.Moore, R.A., Walcott, S., White, K.L., Anderson, D.M., Jain, S., Lloyd, A.,
Topley, P., Thomsen, L., Gough, G.W., Stanley, M.A., 2003. Therapeutic
immunisation with COPVearly genes by epithelial DNA delivery. Virology
314, 630–635.
Nicholls, P.K., Klaunberg, B.A., Moore, R.A., Santos, E.B., Parry, N.R., Gough,
G.W., Stanley, M.A., 1999. Naturally occurring, nonregressing canine oral
papillomavirus infection: host immunity, virus characterization, and
experimental infection. Virology 265, 365–374.
Nicholls, P.K., Moore, P.F., Anderson, D.M., Moore, R.A., Parry, N.R., Gough,
G.W., Stanley, M.A., 2001. Regression of canine oral papillomas is
associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 283,
31–39.
O’Mahony, C., 2005. Genital warts: current and future management options.
Am. J. Clin. Dermatol. 6, 239–243.
Okabayashi, M., Angell, M.G., Christensen, N.D., Kreider, J.D., 1991.
Morphometric analysis and identification of infiltrating leucocytes in
regressing and progressing Shope rabbit papillomas. Int. J. Cancer 49,
919–923.
Padma, T.V., 2005. Experts inject reality into cervical cancer prevention
schemes. Nat. Med. 11, 359.
Peh, W.L., Middleton, K., Christensen, N., Nicholls, P., Egawa, K., Sotlar, K.,
Brandsma, J., Percival, A., Lewis, J., Liu, W.J., Doorbar, J., 2002. Life cycle
heterogeneity in animal models of human papillomavirus-associated disease.
J. Virol. 76, 10401–10416.
Richards, C.A., Brown, C.E., Cogswell, J.P., Weiner, M.P., 2000. The admid
system: generation of recombinant adenoviruses by Tn7-mediated transpo-
sition in E. coli. Biotechniques 29, 146–154.
Selvakumar, R., Ahmed, R., Wettstein, F.O., 1995a. Tumor regression is
associated with a specific immune response to the E2 protein of cottontail
rabbit papillomavirus. Virology 208, 298–302.
Selvakumar, R., Borenstein, L.A., Lin, Y.L., Ahmed, R., Wettstein, F.O., 1995b.
Immunization with nonstructural proteins E1 and E2 of cottontail rabbit
papillomavirus stimulates regression of virus-induced papillomas. J. Virol.
69, 602–605.
Stanley, M.A., Moore, R.A., Nicholls, P.K., Santos, E.B., Thomsen, L.,
Parry, N., Walcott, S., Gough, G., 2001. Intra-epithelial vaccination with
COPV L1 DNA by particle-mediated DNA delivery protects against
mucosal challenge with infectious COPV in beagle dogs. Vaccine 19,
2783–2792.
Suzich, J.A., Ghim, S.J., Palmer Hill, F.J., White, W.I., Tamura, J.K., Bell, J.A.,
Newsome, J.A., Jenson, A.B., Schlegel, R., 1995. Systemic immunization
with papillomavirus L1 protein completely prevents the development of
viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92, 11553–11557.
van Poelgeest, M.I., van Seters, M., van Beurden, M., Kwappenberg, K.M.,
Heijmans-Antonissen, C., Drijfhout, J.W., Melief, C.J., Kenter, G.G.,
Helmerhorst, T.J., Offringa, R., van der Burg, S.H., 2005. Detection of
human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in
patients with persistent HPV16-induced vulvar intraepithelial neoplasia in
relation to clinical impact of imiquimod treatment. Clin. Cancer Res. 11,
5273–5280.
van Rooij, E.M., Haagmans, B.L., de Visser, Y.E., de Bruin, M.G., Boersma,W.,
Bianchi, A.T., 1998. Effect of vaccination route and composition of DNA
vaccine on the induction of protective immunity against pseudorabies
infection in pigs. Vet. Immunol. Immunopathol. 66, 113–126.
Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R.,
Wheeler, C.M., Koutsky, L.A., Malm, C., Lehtinen, M., Skjeldestad, F.E.,
Olsson, S.E., Steinwall, M., Brown, D.R., Kurman, R.J., Ronnett, B.M.,
Stoler, M.H., Ferenczy, A., Harper, D.M., Tamms, G.M., Yu, J.,
Lupinacci, L., Railkar, R., Taddeo, F.J., Jansen, K.U., Esser, M.T.,
Sings, H.L., Saah, A.J., Barr, E., 2005. Prophylactic quadrivalent human
papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in
young women: a randomised double-blind placebo-controlled multicentre
phase II efficacy trial. Lancet Oncol. 6, 271–278.
Vinner, L., Nielsen, H.V., Bryder, K., Corbet, S., Nielsen, C., Fomsgaard, A.,
1999. Gene gun DNA vaccination with Rev-independent synthetic HIV-1
gp160 envelope gene using mammalian codons. Vaccine 17, 2166–2175.
Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A.,
Shah, K.V., Snijders, P.J., Peto, J., Meijer, C.J., Munoz, N., 1999. Human
34 S. Jain et al. / Virology 356 (2006) 23–34papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J. Pathol. 189, 12–19.
Welters, M.J., de Jong, A., van den Eeden, S.J., van der Hulst, J.M.,
Kwappenberg, K.M., Hassane, S., Franken, K.L., Drijfhout, J.W., Fleuren,
G.J., Kenter, G., Melief, C.J., Offringa, R., van der Burg, S.H., 2003.
Frequent display of human papillomavirus type 16 E6-specific memory
t-Helper cells in the healthy population as witness of previous viral encounter.
Cancer Res. 63, 636–641.
Welters, M.J.P., van der Logt, P., van den Eeden, S.J.F., Kwappenberg, K.M.C.,
Drijfhout, J.W., Fleuren, G.J., Kenter, G.G., Melief, C.J.M., van der Burg,S.H., Offringa, R., 2006. Detection of human papillomavirus type 18 E6
and E7-specific CD4+ T-helper 1 immunity in relation to health versus
disease. Int. J. Cancer 118, 950–956.
Zhou, J., Liu, W.J., Peng, S.W., Sun, X.Y., Frazer, I., 1999. Papillomavirus
capsid protein expression level depends on the match between codon usage
and tRNA availability. J. Virol. 73, 4972–4982.
zur Megede, J., Chen, M.C., Doe, B., Schaefer, M., Greer, C.E., Selby, M.,
Otten, G.R., Barnett, S.W., 2000. Increased expression and immunogenicity
of sequence-modified human immunodeficiency virus type 1 gag gene.
J. Virol. 74, 2628–2635.
